BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...its oncology business group. Before joining Eisai, Woodman was CMO and head of R&D of Onconova Therapeutics Inc....
BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

...for the oral semi-synthetic taxane derivative to FDA in mid-2021.Onconova down on survival data for rigosertibShares of Onconova Therapeutics Inc....
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...Inc. (NASDAQ:AGIO), Laboratory Corp. of America Holdings (NYSE:LH) and Onconova Therapeutics Inc....
BioCentury | Jan 9, 2020
Company News

Pfizer dips into translational regulation for cancer with eFFECTOR deal

...already been identified. He declined to disclose the responsibilities of each party in the deal. Onconova Therapeutics Inc....
BioCentury | Dec 19, 2019

Inhibiting the EIF4G1-EIF4E interaction to treat autism

...dendritic spine density. Next steps include testing the EIF4G1-EIF4E inhibitor in other models of autism. Onconova Therapeutics Inc....
BioCentury | May 13, 2019
Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

...8.5 Months in AFP-High HCC Population" ). HanX gains Chinese rights to Onconova's MDS therapy Onconova Therapeutics Inc....
...rigosertib sodium (ON 01910.Na, estybon, iv rigosertib) Eli Lilly and Co. Grail Inc. HanX Biopharmaceuticals Inc. JCR Pharmaceuticals Co. Ltd. Onconova Therapeutics Inc. PeptiDream...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Japanese NDA 1H19 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost insert Glaucoma Phase III data 1H19 Onconova Therapeutics Inc....
BioCentury | May 4, 2018
Financial News

Onconova prices $25M follow-on

...Cancer company Onconova Therapeutics Inc. (NASDAQ:ONTX) raised $25 million on April 27 through the sale of 59 million...
...purchase 1.5 million shares of Onconova's series B convertible preferred stock. Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. Shannon Lehnbeuter Onconova Therapeutics Inc....
BioCentury | Jan 19, 2018
Clinical News

Onconova expands enrollment in Phase III INSPIRE trial of rigosertib in MDS

...rigosertib in Japan and Korea under a 2011 deal (see BioCentury, July 11, 2011 ). Onconova Therapeutics Inc....
...QOL) and hematologic improvement rate Status: Phase III amended Milestone: NA Jaime De Leon IV rigosertib ON 01910.Na SyB L-1101 Onconova Therapeutics Inc. SymBio...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...and decreased memory deficits compared with vehicle. Next steps include development of additional eIF4E-eIF4G1 inhibitors. Onconova Therapeutics Inc....
Items per page:
1 - 10 of 99
BioCentury | Jan 22, 2021
Management Tracks

Woodman to guide Eisai’s cancer unit; plus Mengyu Lu joins Kirkland & Ellis in Hong Kong, and Splice Bio, Tarsus, Verastem, Fulcrum and more

...its oncology business group. Before joining Eisai, Woodman was CMO and head of R&D of Onconova Therapeutics Inc....
BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

...for the oral semi-synthetic taxane derivative to FDA in mid-2021.Onconova down on survival data for rigosertibShares of Onconova Therapeutics Inc....
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

...Inc. (NASDAQ:AGIO), Laboratory Corp. of America Holdings (NYSE:LH) and Onconova Therapeutics Inc....
BioCentury | Jan 9, 2020
Company News

Pfizer dips into translational regulation for cancer with eFFECTOR deal

...already been identified. He declined to disclose the responsibilities of each party in the deal. Onconova Therapeutics Inc....
BioCentury | Dec 19, 2019

Inhibiting the EIF4G1-EIF4E interaction to treat autism

...dendritic spine density. Next steps include testing the EIF4G1-EIF4E inhibitor in other models of autism. Onconova Therapeutics Inc....
BioCentury | May 13, 2019
Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

...8.5 Months in AFP-High HCC Population" ). HanX gains Chinese rights to Onconova's MDS therapy Onconova Therapeutics Inc....
...rigosertib sodium (ON 01910.Na, estybon, iv rigosertib) Eli Lilly and Co. Grail Inc. HanX Biopharmaceuticals Inc. JCR Pharmaceuticals Co. Ltd. Onconova Therapeutics Inc. PeptiDream...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Japanese NDA 1H19 Ocular Therapeutix Inc. (NASDAQ:OCUL) Sustained-release travoprost insert Glaucoma Phase III data 1H19 Onconova Therapeutics Inc....
BioCentury | May 4, 2018
Financial News

Onconova prices $25M follow-on

...Cancer company Onconova Therapeutics Inc. (NASDAQ:ONTX) raised $25 million on April 27 through the sale of 59 million...
...purchase 1.5 million shares of Onconova's series B convertible preferred stock. Onconova Therapeutics Inc. (NASDAQ:ONTX), Newton, Pa. Shannon Lehnbeuter Onconova Therapeutics Inc....
BioCentury | Jan 19, 2018
Clinical News

Onconova expands enrollment in Phase III INSPIRE trial of rigosertib in MDS

...rigosertib in Japan and Korea under a 2011 deal (see BioCentury, July 11, 2011 ). Onconova Therapeutics Inc....
...QOL) and hematologic improvement rate Status: Phase III amended Milestone: NA Jaime De Leon IV rigosertib ON 01910.Na SyB L-1101 Onconova Therapeutics Inc. SymBio...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...and decreased memory deficits compared with vehicle. Next steps include development of additional eIF4E-eIF4G1 inhibitors. Onconova Therapeutics Inc....
Items per page:
1 - 10 of 99